FOLH1 and prostate cancer: In a meta-analysis of seven studies compromising 389 patients undergoing initial diagnosis of prostate cancer, PSMA positron emission tomography/computed tomography (PET/CT) demonstrated a pooled sensitivity and specificity of 0.97 and 0.66, respectively, with a positive likelihood ratio of 2.86 and negative likelihood ratio of 0.05 demonstrating that PSMA PET/CT is a useful technique for excluding malignancy in patients with clinical suspicion of prostate cancer, thus avoiding unnecessary biopsies (5).